About United BioPharma

United BioPharma (UBP), founded in 2013 as a spin-off from its parent, UBIAsia, is a leading biopharmaceutical company based in Taiwan, dedicated to the research, development and manufacturing of novel therapeutic monoclonal antibodies (mAbs) for infectious, cancerous and immunological diseases. UBP’s operating bases include an R&D and manufacturing center in the Hsinchu Industrial Park (Hukou, Taiwan), a clinical research center in the Hsinchu Biomedical Science Park (Zhubei , Taiwan), and a business center in Taipei 101 (Taipei, Taiwan). UBP has extended its business to China and established two subsidiary companies: UBP Shanghai with a clinical development center in Zizhu National Hi-Tech Industrial Development Zone and UBP Yangzhou with a manufacturing center in Yangzhou High-Tech Industrial Development Zone.

Our vision is to become a leader in biopharmaceutical arena in Asia; to bring hope and improve patients’ quality of life. Our mission is to develop high-impact and novel mAb medicines, resolving the unmet medical need for major diseases.

UBP has several unique, competitive and synergistic advantages that differentiate us to other biotech companies and position us toward foreseeable success. These include the rich global resources within our group of companies (UBI group), a talented and high - quality team with the support from worldwide collaborators, two high-value technology platforms, the state-of-the-art infrastructure for R&D and manufacturing, and high market value antibody drug candidates. All these strengths will lead us to breakthrough growth and heightening our rate of product development.